Indications, dosage, side effects and precautions of capmatinib

The use of Capmatinib is focused on the treatment of exon 14skipping mutant NSCLC , providing patients with an innovative and promising treatment strategy that greatly improves the prognosis and quality of life of patients with this specific subtype of lung cancer.

1. Indications: Capmatinib is a targeted therapy drug used to treat MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC). METExon 14 skipping mutation is a relatively rare but biologically important genetic mutation in NSCLC patients. It leads to abnormal activation of MET kinase, thereby promoting the development of lung cancer. Therefore, capmatinib is mainly suitable for patients carrying this mutation.

2. Dose:

Individualized dosage: The dosage of capmatinib is usually adjusted by the physician based on the patient's weight, liver function, overall health, and other individualized factors. Individualization of dosage helps ensure patients receive optimal treatment results while minimizing potential adverse effects.

Oral administration: Capmatinib is an oral drug. Patients should strictly follow the doctor's recommendations to take the drug orally at the same time every day. It can be taken with food or on an empty stomach. The continued use of the drug requires the patient to cooperate with the doctor's advice and follow the treatment plan.

3. Side effects:

The use of capmatinib may cause a series of side effects. The occurrence of these side effects may vary depending on individual differences. The following are some common side effects:

Fatigue: Patients may feel tired and weak, which affects daily activities and work.

Nausea and Vomiting: Some patients may experience nausea and vomiting while taking capmatinib, which may affect appetite and weight.

Diarrhea: Drugs may cause diarrhea, and patients should report it to their doctor in time to take appropriate management measures.

Skin rash: Skin reactions such as rashes may occur and patients need to keep their skin clean and avoid overexposure to the sun.

Abnormal liver function: Capmatinib may affect liver function, so doctors will regularly monitor the patient's liver function indicators during treatment.

Hypertension: Some patients may experience high blood pressure while taking capmatinib, and regular monitoring of blood pressure is necessary.

Other discomforts: Including but not limited to joint pain, headache, cough, etc.

4. Notes:

Regular follow-up: During capmatinib treatment, patients need to receive regular medical examinations and follow-up visits to monitor the progression of the disease and evaluate the efficacy of the drug. Follow-up visits also provide doctors with the opportunity to adjust treatment plans.

Drug Interactions: Before starting treatment with capmatinib, patients should inform their doctor of all medications they are taking, including prescription drugs, over-the-counter drugs, and supplements. Certain drugs may interact with capmatinib and affect the effectiveness of the treatment.

Pregnant and lactating women: Capmatinib may have adverse effects on the fetus, so female patients must take effective contraceptive measures during treatment to prevent pregnancy. Female patients should avoid breastfeeding during treatment.

Timely reporting of adverse reactions: Patients should promptly report any discomfort and symptom changes to their doctors when using capmatinib, so that doctors can adjust the treatment plan in a timely manner.

Lifestyle adjustments: Patients may need to adjust their lifestyle during treatment, such as paying attention to their diet, maintaining adequate rest, and exercising moderately, to promote recovery and improve quality of life.

Capmatinib, as an innovative targeted therapy, has shown good efficacy in the treatment of NSCLC patients with MET exon 14 skipping mutations. However, patients should closely follow their doctor's advice when using the drug and report any adverse reactions promptly to ensure the safe and effective use of the drug. Doctors will adjust the treatment plan according to the patient's condition and response to provide patients with a better treatment experience and quality of life.

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive. Generic drugs on the market abroad are much cheaper, mainly Laos generic drugs, the price is around 3,000 to 4,000 yuan, and the ingredients of original drugs and generic drugs are basically the same.